Literature DB >> 3514103

Branhamella catarrhalis--an emerging human pathogen.

G V Doern.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3514103     DOI： 10.1016/0732-8893(86)90098-2

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


× No keyword cloud information.
  26 in total

1.  Interpretation of gram-stained sputa containing Moraxella (Branhamella) catarrhalis.

Authors:  S M Ainsworth; S B Nagy; L A Morgan; G R Miller; J L Perry
Journal:  J Clin Microbiol       Date:  1990-11       Impact factor: 5.948

2.  Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study.

Authors:  G V Doern; A B Brueggemann; G Pierce; T Hogan; H P Holley; A Rauch
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 3.  Cost-effective treatment of lower respiratory tract infections.

Authors:  J C Garrelts; A M Herrington
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

4.  Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis.

Authors:  X X Gu; J Chen; S J Barenkamp; J B Robbins; C M Tsai; D J Lim; J Battey
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

5.  Disk diffusion susceptibility of Branhamella catarrhalis and relationship of beta-lactam zone size to beta-lactamase production.

Authors:  I Luman; R W Wilson; R J Wallace; D R Nash
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

Review 6.  Antimicrobial susceptibility testing of Haemophilus influenzae, Branhamella catarrhalis, and Neisseria gonorrhoeae.

Authors:  G V Doern; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

7.  Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

8.  A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model.

Authors:  M E Helminen; I Maciver; J L Latimer; L D Cope; G H McCracken; E J Hansen
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

9.  Effect of inoculum size on results of macrotube broth dilution susceptibility tests with Branhamella catarrhalis.

Authors:  G V Doern; T Tubert
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

10.  Lack of serotype-specific antibody response to lipopolysaccharide antigens of Moraxella catarrhalis during lower respiratory tract infection.

Authors:  M Rahman; T Holme; I Jönsson; A Krook
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.